Stereochemistry | RACEMIC |
Molecular Formula | C13H17NO2 |
Molecular Weight | 219.2796 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CCCCN1)[C@H](C(O)=O)C2=CC=CC=C2
InChI
InChIKey=INGSNVSERUZOAK-VXGBXAGGSA-N
InChI=1S/C13H17NO2/c15-13(16)12(10-6-2-1-3-7-10)11-8-4-5-9-14-11/h1-3,6-7,11-12,14H,4-5,8-9H2,(H,15,16)/t11-,12-/m1/s1
Molecular Formula | C13H17NO2 |
Molecular Weight | 219.2796 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ritalinic acid is an inactive, major metabolite of methylphenidate, a schedule II drug in the United States commonly used as a psychostimulant drugs methylphenidate and ethylphenidate. The elimination half-life of methylphenidate is relatively short (approximately 2 hours); therefore it is also available in extended release (ER) forms. The main metabolite is ritalinic acid, and the methylphenidate metabolites are mostly excreted in urine.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|